Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid Cancer

by Robinson, Bruce, Schlumberger, Martin, Wirth, Lori J., Dutcus, Corina E., Song, James, Taylor, Matthew H., Kim, Sung-Bae, Krzyzanowska, Monika K., Capdevila, Jaume, Sherman, Steven I., Tahara, Makoto
Published 2016

Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine‐refractory differentiated thyroid cancer

by Kiyota, Naomi, Schlumberger, Martin, Muro, Kei, Ando, Yuichi, Takahashi, Shunji, Kawai, Yasukazu, Wirth, Lori, Robinson, Bruce, Sherman, Steven, Suzuki, Takuya, Fujino, Katsuki, Gupta, Anubha, Hayato, Seiichi, Tahara, Makoto
Published 2015

The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors

by Rosen, Lee S, Lipton, Lara, Price, Timothy J, Belman, Neil D, Boccia, Ralph V, Hurwitz, Herbert I, Stephenson Jr, Joe J, Wirth, Lori J, McCoy, Sheryl, Hei, Yong-jiang, Hsu, Cheng-Pang, Tebbutt, Niall C
Published 2013

Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study)

by Fayette, Jérôme, Wirth, Lori, Oprean, Cristina, Udrea, Anghel, Jimeno, Antonio, Rischin, Danny, Nutting, Christopher, Harari, Paul M., Csoszi, Tibor, Cernea, Dana, O’Brien, Paul, Hanley, William D., Kapp, Amy V., Anderson, Maria, Penuel, Elicia, McCall, Bruce, Pirzkall, Andrea, Vermorken, Jan B.
Published 2016